Tags

Type your tag names separated by a space and hit enter

Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
Eur Neuropsychopharmacol. 2008 Nov; 18(11):803-13.EN

Abstract

The efficacy and safety of Hypericum extract WS 5570 in preventing relapse during 6 months' continuation treatment and 12 months' long-term maintenance treatment after recovery from an episode of recurrent depression were investigated in a double-blind, placebo controlled multicenter trial. Adult out-patients with a recurrent episode of moderate major depression, a 17-item Hamilton Depression Rating Scale (HAMD) total score > or =20 and > or =3 previous episodes in 5 years participated. After 6 weeks of single-blind treatment with 3 x 300 mg/day WS 5570 patients with score < or =2 on item 'Improvement' of the Clinical Global Impressions (CGI) scale and a HAMD total score decrease > or =50% versus baseline were randomized to 3 x 300 mg/day WS 5570 or placebo for 26 weeks. 426 patients were evaluated for efficacy. Relapse rates during continuation treatment were 51/282 (18.1%) for WS 5570 and 37/144 (25.7%) for placebo. Average time to relapse was 177+/-2.8 and 163+/-4.4 days for WS 5570 and placebo, respectively (time-to-event analysis; p=0.034; alpha=0.025 one-sided). Patients treated with WS 5570 showed more favorable HAMD and Beck Depression Inventory time courses and greater over-all improvement (CGI) than those randomized to placebo. In long-term maintenance treatment a pronounced prophylactic effect of WS 5570 was observed in patients with an early onset of depression as well as in those with a high degree of chronicity. Adverse event rates under WS 5570 were comparable to placebo. WS 5570 showed a beneficial effect in preventing relapse after recovery from acute depression. Tolerability in continuation and long-term maintenance treatment was on the placebo level.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kasper S
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, Austria. sci-biolpsy@meduniwien.ac.at
Volz HP
No affiliation info available
Möller HJ
No affiliation info available
Dienel A
No affiliation info available
Kieser M
No affiliation info available

MeSH

Acute DiseaseAdolescentAdultAgedAntidepressive AgentsDepressive Disorder, MajorDouble-Blind MethodFemaleHumansHypericumMaleMiddle AgedOutpatientsPhytotherapyPlant ExtractsPsychiatric Status Rating ScalesSample SizeSecondary PreventionSertralineTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18694635

Citation

Kasper, S, et al. "Continuation and Long-term Maintenance Treatment With Hypericum Extract WS 5570 After Recovery From an Acute Episode of Moderate Depression--a Double-blind, Randomized, Placebo Controlled Long-term Trial." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 18, no. 11, 2008, pp. 803-13.
Kasper S, Volz HP, Möller HJ, et al. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol. 2008;18(11):803-13.
Kasper, S., Volz, H. P., Möller, H. J., Dienel, A., & Kieser, M. (2008). Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 18(11), 803-13. https://doi.org/10.1016/j.euroneuro.2008.06.006
Kasper S, et al. Continuation and Long-term Maintenance Treatment With Hypericum Extract WS 5570 After Recovery From an Acute Episode of Moderate Depression--a Double-blind, Randomized, Placebo Controlled Long-term Trial. Eur Neuropsychopharmacol. 2008;18(11):803-13. PubMed PMID: 18694635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. AU - Kasper,S, AU - Volz,H P, AU - Möller,H J, AU - Dienel,A, AU - Kieser,M, Y1 - 2008/08/09/ PY - 2008/04/16/received PY - 2008/06/10/revised PY - 2008/06/19/accepted PY - 2008/8/13/pubmed PY - 2008/12/17/medline PY - 2008/8/13/entrez SP - 803 EP - 13 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 18 IS - 11 N2 - The efficacy and safety of Hypericum extract WS 5570 in preventing relapse during 6 months' continuation treatment and 12 months' long-term maintenance treatment after recovery from an episode of recurrent depression were investigated in a double-blind, placebo controlled multicenter trial. Adult out-patients with a recurrent episode of moderate major depression, a 17-item Hamilton Depression Rating Scale (HAMD) total score > or =20 and > or =3 previous episodes in 5 years participated. After 6 weeks of single-blind treatment with 3 x 300 mg/day WS 5570 patients with score < or =2 on item 'Improvement' of the Clinical Global Impressions (CGI) scale and a HAMD total score decrease > or =50% versus baseline were randomized to 3 x 300 mg/day WS 5570 or placebo for 26 weeks. 426 patients were evaluated for efficacy. Relapse rates during continuation treatment were 51/282 (18.1%) for WS 5570 and 37/144 (25.7%) for placebo. Average time to relapse was 177+/-2.8 and 163+/-4.4 days for WS 5570 and placebo, respectively (time-to-event analysis; p=0.034; alpha=0.025 one-sided). Patients treated with WS 5570 showed more favorable HAMD and Beck Depression Inventory time courses and greater over-all improvement (CGI) than those randomized to placebo. In long-term maintenance treatment a pronounced prophylactic effect of WS 5570 was observed in patients with an early onset of depression as well as in those with a high degree of chronicity. Adverse event rates under WS 5570 were comparable to placebo. WS 5570 showed a beneficial effect in preventing relapse after recovery from acute depression. Tolerability in continuation and long-term maintenance treatment was on the placebo level. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/18694635/Continuation_and_long_term_maintenance_treatment_with_Hypericum_extract_WS_5570_after_recovery_from_an_acute_episode_of_moderate_depression__a_double_blind_randomized_placebo_controlled_long_term_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(08)00168-5 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓7]

Related Citations

More